Staying Long Against High-Frequency Traders

Summary

Putting the legal and trading case arguments against the remarks sent out by Citron Research Analyst, March 9, 2020, then threatened, used High-Frequency Trading with short-selling actions immediately the same day to drive down share value of Inovio Pharmaceutical INO.

How different was the announcement by GlaxoSmithKline, GSX, and Sanofi-Aventis S.A., SNY their combined announcement April 14, 2020, in joining developing a vaccine for COVID-19 from that of Inovio INO-4800?

Price-Targets PT Inovio INO

When Citron's law-firms posting of class-action law-suits with their Twitter Tweets broke or challenged SEC laws on SEC 72 hours by setting into motion, their uses of High-Frequency Short-Selling Campaign against Inovio shareholders value. 

Bullish Reversals identified with INO. 

(Click on image to enlarge)

Inovio Stock Roiled With High-Frequency Short-Selling as Citron Research, Law Firms

Push Back on Coronavirus Vaccine Announcement 

DJ News Feeds, March 9, 2020

Citron Research later posted a tweet saying regulators should investigate the "ludicrous and dangerous claim that they designed a vaccine in 3 hours." The Citron Research tweet sent the stock much lower by High-Frequency Trading (HFT) short-selling, driving the INO share price down, giving rise to possible grounds for a lawsuit by investors who lost money, multiple law firms who climbed aboard as HFT and said,

$INO SEC should immediately HALT this stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours. This has been a serial stock promotion for years. This will trade back to $2. Investors have been warned.

— Citron Research (@Citron Research) March 9, 2020

A Common Practice

Lawyers and firms have long made a practice of jumping on the news and putting efforts to drive down shareholder value by HFT short-selling from potentially questionable activity by publicly traded companies as we are commenting on the Inovio by announcing they're seeking shareholders to sue the company.

The degree of success for such lawsuits isn't immediately clear, but often they either aren't filed or don't result in a big win for shareholders.

What Inovio Said:

The law firms all said they were looking into an early March press release from Inovio in which its President and CEO Joseph Kim, said: "We designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19."

The company also said it can develop a vaccine by the end of the year.

Citron Research later posted a tweet saying, regulators should investigate the "ludicrous and dangerous claim that they designed a vaccine in 3 hours." The Citron Research tweet sent the stock lower, giving rise to possible grounds for a lawsuit by investors who lost money, multiple law firms said.

(INO). SEC should immediately HALT this stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours. This has been a serial stock promotion for years. This will trade back to $2. Investors have been warned.

— Citron Research (@Citron Research) March 9, 2020

Among the lawyers and firms seeking investors for a possible suit were Glancy, Prongay & Murray; Howard G. Smith'; Bronstein, Gewirtz & Grossman; and the Pomerantz Law Firm.

THE FACTS

The SEC,  FDA, and all other regulatory agencies have investigated Citron Research Analyst claims have fully reviewed the statements made by Inovio Pharmaceuticals,  Dr. Joseph Kim, as Tweeted by Citron, and cited by law firms who filed Class-Action lawsuits causing downside pressures on shareholders' value.

The SEC and FDA found the statements made by Dr. Kim, CEO of Inovio Pharmaceuticals, to be true, as the FDA approved Inovio’s INO-4800 for Phase1/2 human testing. Furthermore, not only was INO-4800 approved for Phase 1, but it has two active COVID-19 Vaccine trials now in progress for results pending later this Summer in the United States, and in South Korea on the need to protect our U.S. Forces stationed in South Korea and eventually all the world.

Both these Phase 1 / 2 COVID-19 Vaccine-Trials funded by the Department of Defense DOD, CEPI, Bill and Melinda Gates Foundation, along with other funding by a further 150 million diluted share offering with Stifel Nicholas, as filed SEC 8-form. It must also be stated again, President Trump brought aboard, INOVIO, most renowned Epidemiologists to Trump's task force. These renowned Inovio Epidemiologists, brought in the early beginning stages, as stages for advising Vice-president Pence, and President Trump, himself, on what expectations as to death rates and virus spreads. Inovio was instrumental with their help with guidelines developed for the mitigation and containing this newest strain of China’s Novel Coronavirus COVID-19.

Here is the problem we see with Citron and the law suits filed by the news events applied towards INO, but vagrantly miss-using the significant SEC laws of no trading of any kind for 72 hour pre-post news worthy events, as rules for publicly making claims or news worthy events as claims that were not objective, but as subjective, tweeted by Citron--chose to announce and then trade HFT along with law-firms using short-selling  pushing the $INO share price down, with also putting Short-selling orders as traded broke the SEC-law prohibits any potential insider knowledge--as was conducted again, by  more than a few law firms also using HFT within the SEC 72 hour freeze for insider trading advantages, as what we saw occur, with the official / un-official Twitter-Tweet as their form in trying to direct large Short-Selling in High Frequency Traders HFT, as also the planned legal filing announcements tragically played by the law-firms moving the actual total shares of $INO availed for trading in borrowing of these $INO shares to well over 38% of the entire issued $INO shares sold short, as to jump on $INO and drive their share price down towards the threatened, two $2 dollar levels, as promised and threatened by Citron’s Tweet. 

THE MESSAGE 

Citron Research Analyst made a Short-Selling SEC 72 Hour news or subjective comment and brought huge block-trade short-selling traders, alert that the SEC should have halted all Short-Sellers, because of the Twitter Tweet can be considered a volatile statement, in that, the legal class action suits should have been filed against Citron Research for their false claims made against Inovio $INO, in a deliberate act of causing significant shareholder losses due to their Tweet sent, March 9, 2020.

Currently, we have price targets for $INO PT’s near-term and long-term. The near-term PT is $37-$48 dollars a share. The longer-term price-target is between $72 - $98 dollars a share in the 2020-2021 fiscal reporting quarters. We make these PT’s based on Inovio huge pipeline of candidates for FDA approvals over these next two years or less.

THE COMPARISON 

How different was the announcement by Glaxo Smith Kline, $GSX and Sanofi-Aventis S.A., $SNY their combined announcement April 14, 2020

April 6, 2020 02:14 PM ET (BZ Newswire) -- News

Sanofi (NASDAQ: SNY) announces that it has successfully priced tap offerings of EUR 500 million of notes (the "Notes") on two outstanding tranches:

• €250 million fixed-rate notes, increasing the total principal amount of the tranche due April 2025 bearing interest at an annual rate of 1.000% to €1 billion
• €250 million fixed-rate notes, increasing the total principal amount of the tranche due April 2030 bearing interest at an annual rate of 1.500% to €1 billion

The Notes are being issued of the company's Euro Medium Term Note Programme.

The transactions enable the company to lower its average cost of debt and extend the average maturity of its debt.

Sanofi intends to use the net proceeds of the offerings for general corporate purposes.

The transactions enable the company to lower its average cost of debt and extend the average maturity of its debt.

Sanofi intends to use the net proceeds of the offerings for general corporate purposes.

Crédit Agricole CIB, HSBC, Bank of America Securities and Société Générale acted as Global Coordinators and Bookrunners for the offering

Copyright © 2020 Benzinga (BZ Newswire, Financial Market Data & API's - Benzinga). Benzinga does not provide investment advice. All rights reserved. Write to [email protected] with any questions about this content. Subscribe to Benzinga Pro (Benzinga Pro | Fast Stock Market News).

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

• Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
• Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021

PARIS and LONDON – April 14, 2020 - Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculoviral expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.

GSK will contribute its proven pandemic adjuvant technology. The use of an adjuvant can be of importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.

As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone.” says Paul Hudson, Chief Executive Officer, Sanofi. “That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”

“This collaboration brings together two of the world’s largest vaccines companies,” says Emma Walmsley, Chief Executive Officer, GSK. “By combining our scientific expertise, technologies, and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19.”

The combination of a protein-based antigen together with an adjuvant is well-established and used in several vaccines available today. An adjuvant is added to some vaccines to enhance e immune response and has been shown to create a stronger and longer-lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.

The companies plan to initiate phase I clinical trials in the second half of 2020 and, if successful, subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.

FURTHER FACTS AGANIST CITRON AND FILED CLASS-ACTION EFFORTS 

Where are the Twitter Tweets of the law firms filing or that Citron subjective feelings on the GlaxoSmithKline and Sanofi? They are certainly missing their Tweets on $GSK and $SNY as maybe a short-selling candidate’s as Citron had chosen Inovio $INO in their development of a vaccine in a 3 hour start-up period. Remember, INO-4700 was already in active Phase 1 / 2 trials during Summer 2019. The tweaking and following FDA guidelines as well as W.H.O.guidlines with INO-4800 before applying for FDA approvals as clearly stated by Dr. Kim, CEO of Inovio Pharmaceuticals. Make no mistake, we still don't agree with the further delusion of shareholder value by the newest agreement by Inovio and Stifel Nicholas 150 million share offer but know they can use these proceeds for bringing their robust drug pipeline to final market with FDA approvals. 

WHAT'S THE FINAL TRADING MESSAGE

Time to send the message for the Institutional Investors to run back into ownership--long positions, and bring the bullish goring of the short-selling bears on $INO to break their trading funds within their banks...